文献速递糖尿病

达格列净损害2型糖尿病患者口服葡萄糖后对内源性葡萄糖生成的抑制

Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
PubMed 文献 · Diabetes Care · 2022-01-01

研究纳入48例2型糖尿病患者,采用双盲随机交叉设计,分别接受达格列净10 mg、艾塞那肽5 μg皮下注射、两药联用或安慰剂,评估口服葡萄糖负荷后内源性葡萄糖生成(EGP)的变化。结果显示,安慰剂和艾塞那肽组EGP显著下降,而达格列净及联用组EGP下降被削弱,且胰岛素/胰高血糖素比值升高幅度减低。

要点

  • 达格列净使口服葡萄糖后EGP下降被削弱(P<0.05)。
  • 达格列净削弱胰岛素/胰高血糖素比值升高(P<0.05)。
  • 艾塞那肽可显著增加胰岛素/胰高血糖素比值。

核心结论

  • SGLT2抑制剂(SGLT2i)在口服葡萄糖负荷期间可导致内源性葡萄糖生成(EGP)增加。
  • 尽管血浆胰岛素升高且胰高血糖素升高,EGP仍被刺激,提示涉及其他因素。

研究设计与样本

  • 48例2型糖尿病患者接受8小时[3-3H]-葡萄糖输注(方案I),评估对达格列净10 mg、艾塞那肽5 μg皮下注射、达格列净/艾塞那肽联用及安慰剂的EGP反应。
  • 2周后(方案II),患者接受5小时双示踪剂(静脉[3-3H]-葡萄糖和口服[1-14C]-葡萄糖)口服葡萄糖耐量试验(OGTT),试验前分别给予安慰剂、达格列净、艾塞那肽或达格列净/艾塞那肽。

主要发现

  • 方案I中,EGP在安慰剂组从2.16 ± 0.15降至1.57 ± 0.08 mg/kg/min(P < 0.01),在艾塞那肽组从2.13 ± 0.16降至1.58 ± 0.03 mg/kg/min(P < 0.01),在达格列净组(2.04 ± 0.17 vs. 1.94 ± 0.18 mg/kg/min)和达格列净/艾塞那肽组(2.13 ± 0.10 vs. 2.09 ± 0.03 mg/kg/min)保持不变(P = NS)。
  • OGTT期间,EGP在安慰剂组从2.30 ± 0.05降至1.45 ± 0.06 mg/kg/min(P < 0.01),在艾塞那肽组从2.53 ± 0.08降至1.36 ± 0.06 mg/kg/min(P < 0.01);在达格列净组(2.20 ± 0.04 vs. 1.71 ± 0.07 mg/kg/min)和达格列净/艾塞那肽组(2.48 ± 0.05 vs. 1.64 ± 0.07 mg/kg/min),EGP下降被削弱(均P < 0.05)。
  • OGTT期间,胰岛素/胰高血糖素比值在安慰剂组从0.26 ± 0.03升至0.71 ± 0.06 μU/mL per pg/mL,在达格列净组从0.26 ± 0.02升至0.50 ± 0.04 μU/mL per pg/mL,升高幅度被削弱(P < 0.05)。
  • 在艾塞那肽组,胰岛素/胰高血糖素比值显著增加(从0.32 ± 0.03升至1.31 ± 0.08 μU/mL per pg/mL),在达格列净/艾塞那肽组增加幅度被削弱(0.32 ± 0.03 vs. 0.78 ± 0.08 μU/mL per pg/mL)(P < 0.01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effect of SGLT2 inhibitors (SGLT2i) on endogenous glucose production (EGP) in patients with type 2 diabetes after an oral glucose load. RESEARCH DESIGN AND METHODS: Forty-eight patients with type 2 diabetes received an 8-h [3-3H]-glucose infusion (protocol I) to assess EGP response to: 1) dapagliflozin (DAPA), 10 mg; 2) exenatide (EXE), 5 μg s.c.; 3) DAPA/EXE; and 4) placebo (PCB). After 2 weeks (protocol II), patients were restudied with a 5-h double-tracer (i.v. [3-3H]-glucose and oral [1-14C]-glucose) oral glucose tolerance test (OGTT) preceded by PCB, DAPA, EXE, or DAPA/EXE. RESULTS: Protocol I: EGP decreased (P < 0.01) with PCB (2.16 ± 0.15 to 1.57 ± 0.08 mg/kg/min) and EXE (2.13 ± 0.16 to 1.58 ± 0.03) and remained unchanged (P = NS) with DAPA (2.04 ± 0.17 vs. 1.94 ± 0.18) and DAPA/EXE (2.13 ± 0.10 vs. 2.09 ± 0.03). During OGTT, EGP decreased (P < 0.01) with PCB (2.30 ± 0.05 to. 1.45 ± 0.06 mg/kg/min) and EXE (2.53 ± 0.08 to 1.36 ± 0.06); with DAPA (2.20 ± 0.04 vs. 1.71 ± 0.07) and DAPA/EXE (2.48 ± 0.05 vs. 1.64 ± 0.07), the decrease in EGP was attenuated (both P < 0.05). During OGTT, the insulin/glucagon (INS/GCN) ratio increased in PCB (0.26 ± 0.03 vs. 0.71 ± 0.06 μU/mL per pg/mL), whereas in DAPA (0.26 ± 0.02 to 0.50 ± 0.04), the increase was blunted (P < 0.05). In EXE, INS/GCN increased significantly (0.32 ± 0.03 to 1.31 ± 0.08) and was attenuated in DAPA/EXE (0.32 ± 0.03 vs. 0.78 ± 0.08) (P < 0.01). CONCLUSIONS: These findings provide novel evidence that the increase in EGP induced by SGLT2i is present during an oral glucose load. The fact that stimulation of EGP occurs despite elevated plasma insulin and glucagon suggests that additional factors must be involved.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Alatrach M, Agyin C, Solis-Herrera C, et al. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Diabetes Care. 2022. PMID: 35235659. doi:10.2337/dc21-1798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。